Announcement under Regulation 30 of LODR
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd's Board, at its meeting on 14 February 2026, reconstituted three key committees — Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee — with the same three non-executive independent directors (Kasu Sumeela as Chairperson, S. Nagavenkata Hareesh, and Satyam Reddy Gopidi as Members) across all three. Separately, Mr. Ramchandra Reddy Kommula, an Independent Director, ceased to be a Director of the Company with effect from 14 February 2026 upon completion of his tenure. The Board recorded its appreciation for his contributions during his term. The disclosure has been made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.
This is a routine corporate governance update — committee restructuring and the natural end of an independent director's term. No material impact on shareholders or operations is expected; the changes strengthen compliance with statutory requirements.